Genentech Banking On Biomarker Data To Save Avastin In Breast Cancer

Genentech is counting on biomarker data gathered across the Avastin development program – in addition to a new assay developed by parent company Roche – to help it retain the VEGF inhibitor’s accelerated approval in metastatic breast cancer.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet